Plain-English translation of NCT05363111 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This clinical trial is testing a new treatment called 225Ac-DOTA- for patients with multiple myeloma that has stopped responding to standard therapies. The treatment combines a known antibody () with radioactive particles designed to seek out and destroy myeloma cells. Researchers are studying whether this medication is safe and whether it helps control the cancer.
Patients with relapsed or refractory multiple myeloma have limited options after their cancer stops responding to standard treatments. This treatment aims to offer a new approach by combining antibody therapy with radioactive particles that may be more effective against hard-to-treat disease.
You likely qualify if…
You likely don't qualify if…
You would receive two infusions: first a dose of over 45 minutes, then two hours later the radioactive antibody treatment over 20-30 minutes. You would then return for frequent follow-up visits to check your blood work and imaging, starting with weekly visits for 8 weeks, then gradually spacing out to once every 4 weeks, with monitoring continuing for up to 12 months. Blood and bone marrow samples may be collected to understand how the treatment works.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States